Altimmune to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Altimmune (NASDAQ:ALT), a late clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, has announced its participation in two upcoming investor conferences. Management will present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 10:30 a.m. ET, and the H.C. Wainwright Liver Disease Virtual Conference on October 21, 2025, at 7:00 a.m. ET.

Both presentations will feature fireside chats and will be available via webcast through the Events section of Altimmune's website. The company's management team will also be available for one-on-one meetings with investors during these events.

News Market Reaction – ALT

-4.29%

1 alert

-4.29% News Effect

On the day this news was published, ALT declined 4.29%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

• Stifel 2025 Virtual Cardiometabolic Forum
  Tuesday, September 30, 2025
  Fireside Chat at 10:30 a.m. Eastern Time

• H.C. Wainwright Liver Disease Virtual Conference
  Tuesday, October 21, 2025
  Fireside Chat at 7:00 a.m. Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obesity.  For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

This press release was published by a CLEAR® Verified individual.

FAQ

When is Altimmune (ALT) presenting at the Stifel 2025 Virtual Cardiometabolic Forum?

Altimmune will present at the Stifel Virtual Cardiometabolic Forum on Tuesday, September 30, 2025 at 10:30 a.m. Eastern Time.

What time is Altimmune's presentation at the H.C. Wainwright Liver Disease Conference?

Altimmune will present at the H.C. Wainwright Liver Disease Virtual Conference on Tuesday, October 21, 2025 at 7:00 a.m. Eastern Time.

How can investors access Altimmune's conference presentations?

Investors can access the webcasts of both presentations through the Events section of the Altimmune website.

What type of company is Altimmune (ALT)?

Altimmune is a late clinical-stage biopharmaceutical company that develops novel peptide-based therapeutics for liver and cardiometabolic diseases.

Will Altimmune management be available for individual meetings at these conferences?

Yes, Altimmune's management team will be available for one-on-one meetings with investors at both conferences.